US 12,268,786 B2
Methods of improving the solubility and bioavailability of therapeutic agents
Anjani Kumar Jha, Cary, NC (US)
Assigned to MAA Laboratories, Inc., Durham, NC (US)
Filed by MAA Laboratories, Inc., Durham, NC (US)
Filed on Apr. 25, 2022, as Appl. No. 17/727,993.
Application 17/727,993 is a continuation of application No. 16/603,420, granted, now 11,311,493, previously published as PCT/US2018/026522, filed on Apr. 6, 2018.
Claims priority of provisional application 62/482,944, filed on Apr. 7, 2017.
Prior Publication US 2023/0084932 A1, Mar. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/51 (2006.01); A61K 31/196 (2006.01); A61K 31/4535 (2006.01); A61K 31/58 (2006.01); B02C 15/00 (2006.01)
CPC A61K 9/5192 (2013.01) [A61K 9/5138 (2013.01); A61K 31/196 (2013.01); A61K 31/4535 (2013.01); A61K 31/58 (2013.01); B02C 15/00 (2013.01); Y10S 977/773 (2013.01); Y10S 977/906 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A continuous process, comprising:
i) milling a pharmaceutical composition in a ball milling apparatus to produce a milled nanoparticle form of the pharmaceutical composition; wherein the milling is performed in the absence of a solvent component; and
ii) coating the milled nanoparticle form of the pharmaceutical composition with one or more polymers to yield a coated nanoparticle pharmaceutical composition comprising about 10% w/w to about 12% w/w polymer, wherein the coating is performed using a melt extrusion process, a melt blown process, a spunbond process, or a high temperature milling process;
wherein the pharmaceutical composition comprises a therapeutic agent selected from dasatinib, abiraterone, raloxifene, capecitabine, methotrexate, diclofenac, and prednisone, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.